Aptose Biosciences Inc (APTO)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
CEO:
William G. Rice
Employees:
40
5955 AIRPORT ROAD, SUITE 228, ., MISSISSAUGA, CANADA L4V 1R9
647-479-9828

Aptose Biosciences discovers and develops personalized therapies addressing unmet medical needs in oncology. Its clinical programs include APTO-253, which is in Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia (AML) and HR MDS. The company also develops luxeptinib, a dual bromodomain and extra-terminal domain motif motif motif protein and kinase inhibitor program.

Data derived from most recent annual or quarterly report
Market Cap 589.653 Million Shares Outstanding93.005 Million Avg 30-day Volume 357.241 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-0.48
Price to Revenue0.0 Debt to Equity0.0 EBITDA-64.826 Million
Price to Book Value1.6201 Operating Margin0.0 Enterprise Value41.138 Million
Current Ratio10 EPS Growth-0.09 Quick Ratio9.681
1 Yr BETA 1.456 52-week High/Low 6.6 / 0.36 Profit Margin0.0
Operating Cash Flow Growth-27.7743 Altman Z-Score-0.0096 Free Cash Flow to Firm -44.399 Million
Earnings Report2023-08-01
View SEC Filings from APTO instead.

View recent insider trading info

Aptose Biosciences Inc YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding APTO (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding APTO

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 4: filed on 2023-01-23 by PAYNE FLETCHER
  • 4: filed on 2023-01-23 by LEDRU PHILIPPE
  • 4: filed on 2023-01-23 by BURGER DENIS R
  • 4: filed on 2023-01-23 by ASHE CAROL GAIL
  • 4: filed on 2023-01-23 by BEJAR RAFAEL
  • 4: filed on 2022-09-21 by RICE WILLIAM G.
  • 4: filed on 2022-09-21 by PAYNE FLETCHER
  • 4: filed on 2022-09-16 by SEIZINGER BERND R.
  • 3: filed on 2022-09-16 by SEIZINGER BERND R.
  • 4: filed on 2022-07-07 by RICE WILLIAM G.

    • Events (8k)

  • 8-K: filed on 2023-06-05:
    Item 3.03: Material Modifications to Rights of Security Holders
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-05-31:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-05-26:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 3.02: Unregistered Sales of Equity Securities
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-05-23:
    Item 5.07: Submission of Matters to a Vote of Security Holders
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-03-23:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-03-13:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-01-30:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-01-06:
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-12-12:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-12-12:
    Item 8.01: Other Events

    • Proposed Sales (Form 144)

    Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    BURGER DENIS R

    • Director
    		 100,000 2023-01-19 1

    PLATZER ERICH

    • Director
    		 100,000 2023-01-19 1

    PAYNE FLETCHER SR VP & CHIEF FIN. OFFICER

    • Officer
    		 110,000 2023-01-19 4

    VINCENT MARK D.

    • Director
    		 100,000 2023-01-19 1

    WHITEHEAD WARREN

    • Director
    		 100,000 2023-01-19 1

    RICE WILLIAM G. CHAIR, PRESIDENT & CEO

    • Officer
    • Director
    		 913,252 2023-01-19 3

    ASHE CAROL GAIL

    • Director
    		 100,000 2023-01-19 1

    SEIZINGER BERND R.

    • Director
    		 100,000 2023-01-19 3

    BEJAR RAFAEL SR. VP, CHIEF MEDICAL OFFICER

    • Officer
    		 310,000 2023-01-19 1

    LEDRU PHILIPPE CHIEF COMMERCIAL OFFICER

    • Officer
    		 300,500 2023-01-19 1

    LOEWY CAROLINE M

    • FORMER DIRECTOR
    		 0 2022-05-31 0

    MARANGO JOTIN SENIOR VP, CFO, AND CBO

    • Officer
    		 600,000 2022-01-18 0

    WILSON DONALD R. JR.

    DRW COMMODITIES, LLC

    DRW HOLDINGS, LLC

    • 10% Owner
    		 8,895,238 2021-08-03 0

    CHOW GREGORY K. EXECUTIVE VP & CFO

    • Officer
    		 0 2021-01-04 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
    No current insider transactions

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    APTOSE BIOSCIENCES INC APTO 2023-06-07 12:45:04 UTC -8.9969 14.0669 150000
    APTOSE BIOSCIENCES INC APTO 2023-06-05 22:15:04 UTC -3.5558 8.6158 1900000
    APTOSE BIOSCIENCES INC APTO 2023-06-05 21:45:04 UTC -3.5558 8.6158 1900000
    APTOSE BIOSCIENCES INC APTO 2023-06-05 21:15:04 UTC -3.5558 8.6158 1900000
    APTOSE BIOSCIENCES INC APTO 2023-06-05 20:45:04 UTC -3.5558 8.6158 1900000
    APTOSE BIOSCIENCES INC APTO 2023-06-05 20:15:05 UTC -3.5558 8.6158 1900000
    APTOSE BIOSCIENCES INC APTO 2023-06-05 19:45:04 UTC -3.5558 8.6158 1900000
    APTOSE BIOSCIENCES INC APTO 2023-06-05 19:15:04 UTC -3.7043 8.7643 1900000
    APTOSE BIOSCIENCES INC APTO 2023-06-05 18:45:03 UTC -3.7043 8.7643 1900000
    APTOSE BIOSCIENCES INC APTO 2023-06-05 18:15:04 UTC -3.7043 8.7643 1900000
    APTOSE BIOSCIENCES INC APTO 2023-06-05 17:45:03 UTC -3.7043 8.7643 1900000
    APTOSE BIOSCIENCES INC APTO 2023-06-05 17:15:03 UTC -3.7043 8.7643 1900000
    APTOSE BIOSCIENCES INC APTO 2023-06-05 16:45:03 UTC -3.6654 8.7254 1900000
    APTOSE BIOSCIENCES INC APTO 2023-06-05 16:15:04 UTC -3.6654 8.7254 1900000
    APTOSE BIOSCIENCES INC APTO 2023-06-05 15:45:04 UTC -3.6654 8.7254 1900000
    APTOSE BIOSCIENCES INC APTO 2023-06-05 15:15:04 UTC -3.6654 8.7254 1900000
    APTOSE BIOSCIENCES INC APTO 2023-06-05 14:45:04 UTC -3.6654 8.7254 1900000
    APTOSE BIOSCIENCES INC APTO 2023-06-05 14:15:04 UTC -3.6654 8.7254 1900000
    APTOSE BIOSCIENCES INC APTO 2023-06-05 13:45:04 UTC -2.1756 7.2356 1600000
    APTOSE BIOSCIENCES INC APTO 2023-06-05 13:15:04 UTC -2.1756 7.2356 1600000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    Elevate your investments